allied academies
World Summit on
Healthcare & Hospital Management
&
International Conference & Exhibition on Biologics and Biosimilars
March 26-27, 2018 | Orlando, USA

Stanley Hong

Celltrion Healthcare, South Korea

Market uptake of mAb biosimilars and their pharmacoeconomics

Many monoclonal antibody biosimilar products are coming on the market since the world first mAb biosimilar, which was Infliximab biosimilar, was approved by EMA and commercialized in 2013. In the beginning of commercialization, there has been lots of resistance from Healthcare Professionals (HCPs) mainly because of their concerns about efficacy and safety. In particular, many HCPs wanted to see more data about the immunogenicity and other side effect profiles. Now, market accessibility of mAb biosimilars has been improved a lot and potential concerns of HCP communities are substantially reducing because much more data about efficacy and side effects including immunogenicity of biosimilar products became available from real world experience as well as additional clinical trials. In terms of pharmacoeconomics, actually huge amount of healthcare budget can be saved from using mAb biosimilars and then the saved budget can be used for the biologic treatment of much more patients and supporting other stakeholders. In another words, the benefit from biosimilars can be distributed back to HCPs. The agenda of this presentation will be development of biosimilars including quality, market accessibility and their pharmacoeconomics.

Speaker Biography

Stanley Hong is a Senior Adviser at the Celltrion Healthcare and has played an important part in its development and success. He was the President of Research and Development at Celltrion, Inc., where he was responsible for the entire R&D including product discovery as well as biosimilar development. His team led the successful development of REMSIMA™, the world's first biosimilar, and gained approval for the product in Korea, Japan, Canada, European Union and USFDA. He was also responsible for the development of other biosimilars in Celltrion and has presented data on biosimilars at national and international medical meetings. He was also the President and CEO of Celltrion Healthcare.

e: seungsuh.hong@celltrion.com

Notes: